Pharvaris N.V. (PHVS) Discusses Topline Data From RAPIDe-3 Phase III Study of Deucrictibant for Hereditary Angioedema Transcript [Seeking Alpha]
Pharvaris N.V. - Ordinary Shares (PHVS)
Company Research
Source: Seeking Alpha
Company Participants Maggie Beller Berndt A. Modig - Co-Founder, CEO & Executive Director Peng Lu - Chief Medical Officer Wim Souverijns - Chief Commercial Officer Conference Call Participants Marc Riedl Maxwell Skor - Morgan Stanley, Research Division Joseph Schwartz - Leerink Partners LLC, Research Division Steven Seedhouse - Cantor Fitzgerald & Co., Research Division Jeffrey Jones - Oppenheimer & Co. Inc., Research Division Laura Chico - Wedbush Securities Inc., Research Division Sushila Hernandez Jacob Mekhael - KBC Securities NV, Research Division Patrick Trucchio - H.C. Wainwright & Co, LLC, Research Division Presentation Operator Good day and thank you for standing by. Welcome to the RAPIDe-3 topline data webcast. [Operator Instructions] I would now like to hand the conference over to your speaker, Maggie, please go ahead. Maggie Beller Thank you, and welcome to the top line data announcement of RAPIDe-3, a Phase III clinical study of deuc
Show less
Read more
Impact Snapshot
Event Time:
PHVS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PHVS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PHVS alerts
High impacting Pharvaris N.V. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
PHVS
News
- Pharvaris (NASDAQ:PHVS) had its "buy" rating reaffirmed by analysts at Guggenheim.MarketBeat
- Pharvaris (NASDAQ:PHVS) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc..MarketBeat
- Pharvaris (NASDAQ:PHVS) had its price target raised by analysts at Bank of America Corporation from $27.00 to $30.00. They now have a "neutral" rating on the stock.MarketBeat
- Pharvaris (PHVS) Is Up 5.9% After Phase 3 RAPIDe-3 Win - Has The Bull Case Changed? [Yahoo! Finance]Yahoo! Finance
- Pharvaris (NASDAQ:PHVS) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.MarketBeat
PHVS
Earnings
- 11/12/25 - Beat
PHVS
Sec Filings
- 12/4/25 - Form 144
- 12/3/25 - Form 144
- 12/3/25 - Form 144
- PHVS's page on the SEC website